ExpreS2ion Biotech to Cut Workforce to Five to Focus on Lead Immunotherapy

MT Newswires · 2d ago
12:45 AM EST, 11/20/2026 (MT Newswires) -- ExpreS2ion Biotech (EXPRS2.ST) will reduce its workforce to five employees from 21 during 2027 as part of a restructuring aimed at lowering costs and prioritizing its lead HER2-targeted immunotherapy ES2B-C001 for breast cancer. The measures are expected to reduce operating costs by 23 million kronor in 2027 and 30 million kronor annually from 2028, once fully implemented in the second half of 2027. Restructuring costs, mainly severance pay and pay during notice periods, are estimated at up to 5 million kronor. The biotechnology company added that its board is evaluating financing alternatives.